NCE-1 Intelligence & Market Opportunity

Vanflyta

Quizartinib

Anticancer

Tablet

Vanflyta is an oral medicine used with chemotherapy for adults newly diagnosed with FLT3‑ITD positive acute myeloid leukemia. It continues working as a maintenance therapy to help keep the cancer in check.

Approval Date

20-Jul-23

NCE-1 Date

20-Jul-27

NCE Date

20-Jul-28

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

0.249

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

100

2028

113

2029

129

2030

147

2031

159

2032

171

Molecule profile

Details & specifications

Molecule

Quizartinib

Innovator

DAIICHI SANKYO INC

Dosage Form

Tablet

Strength

17.7 mg and 26.5 mg base

Therapeutic Category

Anticancer

Usage

To use as part of a treatment regimen for newly diagnosed acute myeloid leukemia that meets certain criteria

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.